JPS6018399B2 - Efficient production method of interferon - Google Patents

Efficient production method of interferon

Info

Publication number
JPS6018399B2
JPS6018399B2 JP57189245A JP18924582A JPS6018399B2 JP S6018399 B2 JPS6018399 B2 JP S6018399B2 JP 57189245 A JP57189245 A JP 57189245A JP 18924582 A JP18924582 A JP 18924582A JP S6018399 B2 JPS6018399 B2 JP S6018399B2
Authority
JP
Japan
Prior art keywords
cells
culture
medium
interferon
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP57189245A
Other languages
Japanese (ja)
Other versions
JPS5982094A (en
Inventor
征二 佐藤
一雄 川村
宣男 藤吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP57189245A priority Critical patent/JPS6018399B2/en
Publication of JPS5982094A publication Critical patent/JPS5982094A/en
Publication of JPS6018399B2 publication Critical patent/JPS6018399B2/en
Expired legal-status Critical Current

Links

Description

【発明の詳細な説明】 インターフェロン(以下IFNと略す)の生産には、白
血球、リンパ芽球様細胞、センィ芽細胞、ヒト群膜細胞
などを培養し、一定細胞濃度に達した後、該細胞を単離
し、もしくは単離しないで種々のウイルスや合成二本鎖
RNA(poly l:C)などの誘発剤で誘発し、I
FNを誘導する方法が知られている。
[Detailed Description of the Invention] Interferon (hereinafter abbreviated as IFN) is produced by culturing leukocytes, lymphoblastoid cells, seniblastocytes, human membrane cells, etc., and after reaching a certain cell concentration, the cells are Isolated or not isolated, induced with various inducers such as viruses or synthetic double-stranded RNA (poly l:C),
Methods of inducing FN are known.

びN‘ま誘発剤処理後、数時間後より細胞から分泌され
、一定時間後には、その力価は一定の値を示す様になる
と考えられている(AntimicroboaIAge
nt and Chemo仇eraphy、20(1)
5、1981)。
Antimicroboa IAge is secreted from cells several hours after treatment with an antimicrobial agent, and its titer is thought to reach a certain value after a certain period of time (Antimicroboa IAge).
nt and Chemo eraphy, 20(1)
5, 1981).

これらの知見より、従来、『Nの生産は自発産生細胞に
よるびNの生産を除いては、その培地中に分泌されたび
Nを一度、採取するのみであった。本発明者らは、用い
る細胞の増殖生理と、培養条件等を種々検討した結果、
IFN生産館をもはや喪失したと思われる細胞を培養系
より単離し、程よく栄養分を加えた新たな新鮮渚地に再
び添加し浮遊培養を行なったところ、驚くべきことには
、該細胞が再びぼN産生態力を発揮し、箸量の『Nを産
生する事実を見し、出し、これについて本願と同日に出
願される。
Based on these findings, conventionally, except for N production by spontaneously producing cells, N was collected only once every time it was secreted into the medium. As a result of various studies on the growth physiology of the cells used and the culture conditions, the present inventors found that
When we isolated cells that seemed to have lost their IFN production capacity from the culture system, added them to fresh beach soil to which appropriate nutrients had been added, and cultured them in suspension, surprisingly, the cells disappeared again. The application was filed on the same day as the present application, demonstrating the ecological power of N production and discovering the fact that it produces a significant amount of N.

本発明者らは、用いる細胞の増殖生理と培養条件等を更
に検討した結果、必ずしも細胞を単離回収することなく
、該細胞を含む培養液中より培養上蒲を除きつつ、一方
より新鮮塔地を添加することにより、該細胞の『N産生
能力は喪失することなく維持され、びNを箸量生産する
ことを見し、出し本発明を完成した。
As a result of further studies on the growth physiology and culture conditions of the cells used, the present inventors discovered that, without necessarily isolating and recovering the cells, they removed the culture medium from the culture medium containing the cells, and instead added fresh cells. They found that by adding diluted salt, the N-producing ability of the cells was maintained without loss, and that a large amount of N was produced, and the present invention was completed.

本発明によるmNの取得方法を説明すると、例えば、リ
ンパ芽球細胞を用いる場合には、先ず該細胞を高濃度培
養液を調製する。
To explain the method for obtaining mN according to the present invention, for example, when lymphoblastoid cells are used, first a high concentration culture medium is prepared for the cells.

このとき−定濃度までは細胞濃度は濃いほど効率的であ
る。高濃度細胞培養液を得るためには、種々の工夫が行
なわれている。本発明においては新手法により該高濃度
液が調製され、その方法は参考例に示されるが、その詳
細は本願と同日に、同一出願人により出願される新出願
「発明の名称:浮遊細胞の高濃度培養法並びにその袋魔
」に詳述されている。。次いで、得られた細胞液を希釈
するかもしくは該細胞を単離し『N産生に好適な濃度で
新鮮培地に浮遊し誘発剤で処理する。誘発剤の処理に先
立ち、処理剤で処理して該細胞を単機回収し改めて新鮮
済地に再浮遊培養すると一層効果的である。培養開始后
直ちに、もしくは一定時間後より培養上蒲を一方より採
取しつつ、新鮮培地を一方より添加して培養を続けるこ
とにより該細胞は長時間びNを産生しつづけ、用いる細
胞当り従釆の1バッチ法に比し箸量のIFNを産生する
ことが可能となつた。本発明で用いる『N産生用の培地
としては、ペニシリン、ストレプトマイシン、グルタミ
ン、へべス緩衝液等を添加したRPMI−1640若地
、及びイーグルMEM培地が適しており、血清は、種々
の血清が用いられ0.5〜20%、好ましくは3〜10
%が適している。
At this time, the higher the cell concentration, the more efficient it is up to a certain concentration. Various efforts have been made to obtain a highly concentrated cell culture solution. In the present invention, the highly concentrated liquid is prepared by a new method, and the method is shown in the reference example, but the details are described in a new application filed by the same applicant on the same day as the present application. It is detailed in ``High Concentration Cultivation Method and Its Secret Demon''. . Next, the obtained cell fluid is diluted or the cells are isolated, suspended in a fresh medium at a concentration suitable for N production, and treated with an inducing agent. It is more effective to treat the cells with a treatment agent prior to treatment with the inducing agent, collect the cells singly, and resuspend them in fresh soil. Immediately after the start of culture, or after a certain period of time, the culture medium is collected from one side and fresh medium is added from the other side to continue the culture, so that the cells continue to produce N for a long time, and depending on the number of cells per cell used. Compared to the one-batch method, it became possible to produce a chopstick's worth of IFN. As the medium for N production used in the present invention, RPMI-1640 Wakachi medium supplemented with penicillin, streptomycin, glutamine, Hebes buffer, etc., and Eagle's MEM medium are suitable. 0.5-20%, preferably 3-10%
% is suitable.

さらに、インターフェロンの精製分離を容易ならしめる
ためには無血清培地も効果的である。無血清培地として
は上記の培地の血清の替りにインシュリン0.3〜10
0ムタ′の‘、好ましくは1〜10〃夕/叫、トランス
フヱリン0.1〜100ムタ/の‘、好ましくは1〜1
0ムタ/の【、亜セレン酸0.1〜100×10‐7M
、好ましくは0.5〜10×10‐7M、ピルピン酸ナ
トリウム0.1〜100wM、好ましくは0.5〜20
mMを加え、場合により血清アルブミン0.1〜200
〃タ′の‘、好ましくは1〜50〃夕/叫が適している
。さらに種々のホルモン類、ビタミン類などを加えても
良い。処理剤による処理方法についてのべると、リンパ
芽球細胞を用いる場合は、公知の誘発剤で処理する2岬
時間〜4曲時間以前より、ソジウムプチレィト、ジメチ
ルスルホキシド(以下DMSOと略す)、ビタミンA、
5ープロモデオキシウリジンなどの処理剤を単独、もし
くはそれぞれの組合せで処理するとより好ましい結果が
得られる。
Furthermore, a serum-free medium is also effective in facilitating the purification and separation of interferon. As a serum-free medium, use insulin 0.3-10 instead of serum in the above medium.
0 mt', preferably 1 to 10 m/s, transferrin 0.1 to 100 mt/', preferably 1 to 1
0 Muta/[, selenite 0.1-100×10-7M
, preferably 0.5-10x10-7M, sodium pyruvate 0.1-100wM, preferably 0.5-20
Add mM and optionally serum albumin 0.1-200
A value of 1 to 50 m/s is suitable. Furthermore, various hormones, vitamins, etc. may be added. Regarding the treatment method using treatment agents, when lymphoblastoid cells are used, sodium petilate, dimethyl sulfoxide (hereinafter abbreviated as DMSO), vitamin A,
More preferable results can be obtained by treating with a treatment agent such as 5-promodeoxyuridine alone or in combination.

細胞は、上記処理剤で処理した後、無菌的に回収し、新
鮮な培地に再浮遊させNDV(ニューカツスル・デイジ
ーズス・ウイルス)、センダイウイルス(10〜100
0HAu/の上)を用いて誘発する。細胞濃度は1×2
0×16cells′私の範囲であれば良いが、好まし
くは4〜7×1びcells/似が望ましい。センィ芽
細胞に於ては、合成二本鎖RNA(poly l:C)
等により誘発されるが、場合によっては、引き続いて超
議発処理(例えば、シクoヘキサミドとアクチノマィシ
ン○の組合せ)する。
After the cells were treated with the above-mentioned treatment agent, they were collected aseptically and resuspended in a fresh medium.
0 HAu/). Cell concentration is 1×2
It may be within the range of 0x16 cells, but preferably 4 to 7x1 cells/similar. In Senblast cells, synthetic double-stranded RNA (poly l:C)
In some cases, this is followed by hyperstimulatory treatment (for example, a combination of cyclohexamide and actinomycin ○).

これらの譲発処理後、2び〜370下で18〜4乳時間
培養して、インターフェロンを生産せしめる。
After these transfer treatments, the cells are cultured for 18 to 4 hours under 2 to 370℃ to produce interferon.

連続培養に際し、一方から培地上清のみを排出し、一方
より新鮮培地を添加するには、参考例に示されるが如き
装置を用いると好都合である。これらの装置ならびに運
転法は、同日に、同一出願人により出願される。新出願
「発明の名称:浮遊培養の高濃度培養法並びにその袋直
」の中に詳述されている。以下にその大略を記すと培養
槽底部に関口部を有し細胞沈澱管を兼ねた培養上情排出
管と新鮮培地添加用の導管を設けた浮遊細胞の高濃度培
養装置を用い、新鮮培地添加用の導管から培地から培地
を添加しつつ培地上清排出管より培養上清を緋出しつつ
培養を行なえばよい。
During continuous culture, it is convenient to use a device such as the one shown in the reference example to drain only the medium supernatant from one side and add fresh medium from the other side. These devices and operating methods are filed on the same date and by the same applicant. It is detailed in the new application ``Title of the Invention: High-concentration culture method of suspension culture and its packaging.'' The outline of the process is as follows: A high-concentration culture device for suspended cells is used, which has a gate at the bottom of the culture tank, a culture outlet tube that also serves as a cell sedimentation tube, and a conduit for adding fresh medium. Culture may be carried out while adding the medium from the medium through the medium conduit and draining the culture supernatant from the medium supernatant discharge tube.

尚用いる装置は第1〜第3図に示す。The apparatus used is shown in FIGS. 1 to 3.

実施例 1 参考例に記載された高濃度浮遊培養装置を用いて、3%
子牛血清を含むRPMI−164世宅地でナマルバ細胞
を培養し、6×1びcells/のの細胞500叫を得
た無菌体に30小pm、10分間の遠心分離を行い、得
られた細胞を実施例1に示した無血清渚地500の‘に
浮遊しlmM/ディウムブチレィト、1%v/vDMS
Oとなる様に加え、同装置を用い37℃で22時間培養
した。
Example 1 Using the high concentration suspension culture device described in the reference example, 3%
Namalva cells were cultured in RPMI-164 Seitakuchi containing calf serum to obtain 6 x 1 cells/500 cells.The cells were centrifuged at 30 pm for 10 minutes in a sterile body. was suspended in serum-free beach 500' as shown in Example 1, lmM/dium butyrate, 1% v/v DMS.
The cells were then cultured at 37°C for 22 hours using the same apparatus.

培養後、再び細胞を遠心分離して集め、同無血清培地5
00の‘に浮遊させた。500日Au/泌となる様にセ
ンダイウィルスで譲発を行い、8時間、370で培養後
、28午0に移した。
After culturing, the cells were collected by centrifugation again and placed in the same serum-free medium 5.
00' floating. Transfection was carried out with Sendai virus so that Au/secretion was obtained for 500 days, and after culturing at 370°C for 8 hours, the cells were transferred at 28:00.

この時点より、新鮮な無血清培地を15〜20の【/h
rずつ添加し、細胞沈殿管を用い、同じ速度で細胞と培
地上清とを分離し、系外へ取り出し始めた。この上清中
にインターフェロンは回収された。下記に2少時間ごと
のインターフェロン力価を示す。なお、1バッチで行っ
た6×1ぴcells/の‘のmN生産量は42000
u/w‘であった。
From this point, add fresh serum-free medium for 15-20 [/h]
The cells and the medium supernatant were separated at the same speed using a cell sedimentation tube, and then taken out of the system. Interferon was recovered in this supernatant. Interferon titers are shown below every 2 hours. In addition, the mN production amount of 6 × 1 cells/' in one batch was 42,000
It was u/w'.

従って1バッチで行う場合に比べ至適条件が持続し、長
期間生産されたため1バッチで行った場合の31倍のI
FNを得ることができた。参考例 第1図に示す如き1〆(直径約132肋、高さ約24仇
吻)の培養槽に直径2.5功の円筒管容積100凧【を
沈殿管として用いた。
Therefore, the optimal conditions last longer than in the case of one batch, and because the production was carried out for a long time, the I
I was able to get FN. Reference Example A cylindrical tube having a volume of 100 tubes with a diameter of 2.5 tubes was used as a precipitation tube in a culture tank of 1 tube (diameter: about 132 tubes, height: about 24 tubes) as shown in FIG.

培養槽にはRPMI−1640(3%子牛血清添加)堵
地を用い、種細砲としてリンパ芽球細胞であるナマルバ
細胞を7×1ぴcells/叫となる様に接種した。全
容量500の‘に対し10.5泌/hrの速度で上清排
出及び新鮮塔地の添加を行った。なお、ポンプはべりス
タテイクポンプを用いた。蝿枠回転数5仇pm、通気は
16の‘/min、370で培養した。細胞数を血球計
算板を用いて測定した結果を第4図に示す。なお、12
q時間後には細胞濃度は6.6×1ぴcells/泌に
達し、生存率は96.5%であった。比較のために行っ
た細胞沈殿管を用いない場合は、破線のごとく2.2×
1ぴcells′ので細胞の生育は止まった。
RPMI-1640 (added with 3% calf serum) was used in the culture tank, and Namalva cells, which are lymphoblastoid cells, were inoculated at 7×1 cells/cell as seeds. Supernatant discharge and fresh column addition were carried out at a rate of 10.5 secretions/hr for a total volume of 500 cm. The pump used was a veristake pump. Culture was carried out at 370°C with a fly frame rotation speed of 5pm and aeration of 16°/min. The results of measuring the number of cells using a hemocytometer are shown in FIG. In addition, 12
After q hours, the cell concentration reached 6.6×1 cells/secretion, and the survival rate was 96.5%. If the cell sedimentation tube used for comparison is not used, 2.2×
Cell growth stopped after 1 pic.

【図面の簡単な説明】[Brief explanation of drawings]

第1図は変形スピンナーフラスコ(本体ガラス製)を示
す。 1はガラス製の細胞沈澱管(排出口)、2はガラス製塔
地添加口、3はステンレス製のシャフト、4はテフロン
製のサンプリング管、5はステンレス製の空気入り口、
6はステンレス製の空気出口、7はテフロン製の回転軸
、8はテフロン製の回転子、9はシリコン製の止め栓、
10は耐熱性プラスチック製のキャップ、11は槌菌口
を表わす。 1の容量は約120の【、2,3の口径は約7風、4,
5,6の口径は約3肌、7は径約19岬、高さ約3仇豚
、8は径12.5側、長さ約75脚、1 1は口径約4
2柳、長さ約37.5肌である。 第2図は変形スピンナーフラスコの平面図である。 第3図は大型培養槽及び、それを含む細胞高濃度培養装
置の1例を示す。12は、培養槽本体を示し、13は細
胞沈澱管(排出管)を示し、14は頚梓翼を示し、15
は上情排出用ポンプ、16は培地添加用ポンプ、1.7
は添加用塔地槽、18は無菌フィルターを示す。 第4図は実施例1における培養時間(機軸)と、生細胞
数(縦軸)の関係を表わしたものである。 実線1は細胞沈澱管を用いた本発明方法による生細胞数
、点線2は通常の培養法により得られる生細砲数を表わ
す。 第1図 第2図 第3図 第4図
FIG. 1 shows a modified spinner flask (main body made of glass). 1 is a glass cell sedimentation tube (exhaust port), 2 is a glass column addition port, 3 is a stainless steel shaft, 4 is a Teflon sampling tube, 5 is a stainless steel air inlet,
6 is a stainless steel air outlet, 7 is a Teflon rotating shaft, 8 is a Teflon rotor, 9 is a silicone stopper,
10 represents a cap made of heat-resistant plastic, and 11 represents a hammer opening. The capacity of 1 is about 120 [, the caliber of 2 and 3 is about 7 winds, 4,
5 and 6 have a diameter of about 3 feet, 7 has a diameter of about 19 capes and a height of about 3 feet, 8 has a diameter of 12.5 and a length of about 75 legs, 1 and 1 have a diameter of about 4
2 willows, about 37.5 skins long. FIG. 2 is a plan view of the modified spinner flask. FIG. 3 shows an example of a large-scale culture tank and a high-density cell culture device including the same. 12 shows the culture tank main body, 13 shows the cell sedimentation tube (discharge pipe), 14 shows the neck azusa wing, 15
1.7 is a pump for discharging medium, 16 is a pump for adding medium.
18 shows an addition tower base tank and a sterile filter. FIG. 4 shows the relationship between the culture time (axis) and the number of viable cells (vertical axis) in Example 1. Solid line 1 represents the number of live cells obtained by the method of the present invention using a cell sedimentation tube, and dotted line 2 represents the number of live cells obtained by the conventional culture method. Figure 1 Figure 2 Figure 3 Figure 4

Claims (1)

【特許請求の範囲】[Claims] 1 インターフエロン誘発剤により誘発した動物細胞を
、培地に連続的に新鮮培地を添加し、かつ培養上清を分
離しながら培養し、分離した上清中から生成したインタ
ーフエロンを採取することを特徴とするインターフエロ
ンの効率的生産方法。
1. Animal cells induced with an interferon inducer are cultured by continuously adding fresh medium to the culture medium and separating the culture supernatant, and interferon produced from the separated supernatant is collected. An efficient method for producing interferon.
JP57189245A 1982-10-29 1982-10-29 Efficient production method of interferon Expired JPS6018399B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57189245A JPS6018399B2 (en) 1982-10-29 1982-10-29 Efficient production method of interferon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57189245A JPS6018399B2 (en) 1982-10-29 1982-10-29 Efficient production method of interferon

Publications (2)

Publication Number Publication Date
JPS5982094A JPS5982094A (en) 1984-05-11
JPS6018399B2 true JPS6018399B2 (en) 1985-05-10

Family

ID=16238048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57189245A Expired JPS6018399B2 (en) 1982-10-29 1982-10-29 Efficient production method of interferon

Country Status (1)

Country Link
JP (1) JPS6018399B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999422A (en) * 1988-04-15 1991-03-12 Biogen, N.V. Continuous method of refolding proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225671A (en) * 1977-06-10 1980-09-30 Battelle-Institut E.V. Process for the in-vitro biosynthesis of hormones, especially insulin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225671A (en) * 1977-06-10 1980-09-30 Battelle-Institut E.V. Process for the in-vitro biosynthesis of hormones, especially insulin

Also Published As

Publication number Publication date
JPS5982094A (en) 1984-05-11

Similar Documents

Publication Publication Date Title
US4144126A (en) Cell culture method
US4224413A (en) Cell culture method
Polatnick et al. Production and purification of milligram amounts of foot-and-mouth disease virus from baby hamster kidney cell cultures
US4664912A (en) Process for the large scale production of rabies vaccine
Wiktor et al. Chronic rabies virus infection of cell cultures
DK147625B (en) METHOD FOR PRODUCING INTERFERON
CN106540249A (en) A kind of bird flu (H5N1) or the antigen concentrating and purifying process of Porcine reproductive and respiratory syndrome (PRRS) viral vaccine
JPH05503843A (en) Biomass for producing viruses/viral antigens
US3951740A (en) Manufacture of interferon
JPS6018399B2 (en) Efficient production method of interferon
US4169761A (en) Process for the cultivation of viruses
JPH0425796B2 (en)
Ekless et al. Ichthyophthirius multifiliis: axenic isolation and short‐term maintenance in selected monophasic media
CN106256905B (en) A kind of pair of grass carp has the CpG ODN sequence and its application of immune-enhancing activity
JPS6018398B2 (en) Efficient production method of interferon
RU2142816C1 (en) Method of preparing antiherpetic vaccine and medicinal form based on said
CN113046330A (en) Lentivirus and medicine carrying erythroid gene editing system
Hulse et al. Two separable cytoplasmic pools of native ribosomal subunits in chick embryo tissue culture cells
CN105255944B (en) Based on the liver cell in-vitro multiplication method for turning the induction of OPN genes
CN1232643C (en) Nucleic acid vaccine
US3629470A (en) Process for purification of animal rna viruses
RU2057545C1 (en) Method of preparing interferon from swine leukocytes
Rott et al. Alterations in pathogenicity of influenza virus through reassortment.
CN107723279A (en) A kind of defective adenoviral AdC68 GP cultural method
RU2051969C1 (en) Method of bacterial lipopolysaccharide preparing